Suppr超能文献

杜氏肌营养不良症的低骨密度和骨代谢改变:钙和维生素 D 治疗的反应。

Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.

机构信息

Centro Malattie Metaboliche Ossee, Istituto Auxologico Italiano IRCCS, Milan, Italy.

出版信息

Osteoporos Int. 2011 Feb;22(2):529-39. doi: 10.1007/s00198-010-1275-5. Epub 2010 May 11.

Abstract

UNLABELLED

Boys with Duchenne muscular dystrophy often have reduced bone mass and increased fracture risk. In this prospective study on 33 patients, calcifediol (25-OH vitamin D(3)) plus adjustment of dietary calcium to the recommended dose reduced bone resorption, corrected vitamin D deficiency, and increased bone mass in about two-thirds of cases.

INTRODUCTION

Low BMC and BMD and bone metabolism alterations are frequent in boys with Duchenne muscular dystrophy (DMD), especially now that long-term glucocorticosteroid (GC) treatment is the standard of care. This prospective study was designed to evaluate the effects of a first-line treatment (25-OH vitamin D(3) [calcifediol] plus adjustment of dietary calcium to the recommended daily dose) on bone.

METHODS

Thirty-three children with DMD on GC treatment were followed for 3 years: one of observation and two of treatment.

MAIN OUTCOME

spine and total body BMC and BMD increase; secondary outcome: changes in bone turnover markers (C-terminal [CTx] and N-terminal [NTx] telopeptides of procollagen type I; osteocalcin [OC]).

RESULTS

During the observation year, BMC and BMD decreased in all patients. At baseline and after 12 months, serum CTx and urinary NTx were higher than normal; OC and parathyroid hormone at the upper limit of normal; 25-OH vitamin D(3) significantly lower than normal. After 2 years of calcifediol and calcium-rich diet, BMC and BMD significantly increased in over 65% of patients, and bone metabolism parameters and turnover markers normalized in most patients (78.8%). During the observation year, there were four fractures in four patients, while during the 2 years of treatment there were two fractures in two patients.

CONCLUSIONS

Calcifediol plus adequate dietary calcium intake seems to be an effective first-line approach that controls bone turnover, corrects vitamin D deficiency, and increases BMC and BMD in most patients with DMD. Lack of response seems related to persistently high bone turnover.

摘要

目的

杜氏肌营养不良症(DMD)男孩常存在骨量减少和骨折风险增加。本前瞻性研究共纳入 33 例患者,结果发现补充骨化二醇(25-OH 维生素 D3)并将膳食钙调整至推荐剂量可减少骨吸收、纠正维生素 D 缺乏、并使大约三分之二的患者骨量增加。

方法

33 例正在接受糖皮质激素(GC)治疗的 DMD 男孩参与本研究,随访 3 年,其中 1 年为观察期,2 年为治疗期。

主要转归

脊柱和全身 BMC 和 BMD 增加;次要转归:骨转换标志物(I 型胶原 C 端和 N 端肽;骨钙素)变化。

结果

在观察期,所有患者 BMC 和 BMD 均下降。基线和 12 个月时,血清 CTx 和尿 NTx 高于正常,OC 和甲状旁腺激素处于正常上限,25-OH 维生素 D3 显著低于正常。2 年骨化二醇和高钙饮食治疗后,超过 65%的患者 BMC 和 BMD 显著增加,且大多数患者(78.8%)的骨代谢参数和标志物恢复正常。在观察期,4 例患者发生 4 次骨折,而在治疗的 2 年中,2 例患者发生 2 次骨折。

结论

骨化二醇加充足的膳食钙摄入似乎是一种有效的一线治疗方法,可控制骨转换、纠正维生素 D 缺乏,并使大多数 DMD 患者的 BMC 和 BMD 增加。治疗无反应可能与持续高骨转换有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验